Drug Trial Radar · NCT05133531
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
202
Actual
Start
Aug 1, 2022
Primary completion
Sep 28, 2026
Study completion Oct 29, 2026
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching a clinical treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of the study is to see how safe and effective the pozelimab + cemdisiran combination is for people with PNH and how the combination compares with 2 existing treatments: ravulizumab and eculizumab. The pozelimab + cemdisiran combination may be referred to as "study drugs". Ravulizumab and eculizumab may also be called the "comparator drug". The study is looking at several research questions, including: * How effective is the pozelimab + cemdisiran combination compared to ravulizumab? * How effective is pozelimab + cemdisiran combination compared to eculizumab? * What side effects may happen from taking the study drugs? * How much study drugs are in the blood at different times? * Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects)
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
RavulizumabDrug
Administered Intravenous (IV) per the protocol
PozelimabDrug
Administered IV and subcutaneous (SC) per the protocol
CemdisiranDrug
Administered SC per the protocol
EculizumabDrug
Administered IV per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in lactate dehydrogenase (LDH)Time frame: From baseline to week 26
- Transfusion avoidanceTime frame: From post-baseline day 1 through week 26
- Adequate control of hemolysisTime frame: From week 8 through week 26, inclusive
Locations
68 sites in 24 countries. Site status is shown where the registry gives one.
The Oncology Institute of Hope & Innovation
Whittier, California
A Beneficencia Portuguesa de Sao Paulo, BP Mirante
São Paulo, Brazil
Casa de Saude Santa Marcelina
São Paulo, Brazil
Centro de Estudos e Pesquisas em Hematologia e Oncologia
Santo André, São Paulo, Brazil
Toronto General Hospital
Toronto, Ontario, Canada
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Hospital Pablo Tobon Uribe
Medellín, Antioquia, Colombia
George Papanikolaou Hospital
Thessaloniki, Greece
Semmelweis University
Budapest, Hungary
Bhagwan Mahaveer Cancer Hospital and Research Centre (BMCHRC)
Jaipur, India
Malabar Cancer Center, Kerala
Kannur, Kerala, India
Amrita Institute of Medical Sciences (AIMS) and Research Centre Aims
Kochi, Kerala, India
K J Somaiya Super Specialty Hospital & Research Centre
Mumbai, Maharashtra, India
Rajiv Gandhi Cancer Institute & Research Center (RGCIRC) - Rohini Campus
New Delhi, National Capital Territory of Delhi, India
Postgraduate Institute of Medical Education & Research (PGIMER)
Chandigarh, Punjab, India
King George Hospital
Lucknow, Uttar Pradesh, India
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Lucknow, Uttar Pradesh, India
Hematology Citta della Salute e della Scienza di Torino
Turin, Italy
Aou Careggi
Florence, Firenze, Italy
Fondazione Policlinico Universitario A. Gemelli - IRCCS
Rome, Roma, Italy
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
Nagoya, Aichi-ken, Japan
Ogaki Municipal Hospital
Ōgaki, Gifu, Japan
University of Tsukuba Hospital
Tsukuba, Ibaraki, Japan
Matsushita Memorial Hospital
Moriguchi, Osaka, Japan
NTT Medical Center Tokyo
Shinagawa-ku, Tokyo, Japan
Jordan University Hospital (JUH)
Amman, Jordan
Hospital Tg Ampuan Afzan
Kuantan, Pahang, Malaysia
Hospital Queen Elizabeth
Kota Kinabalu, Sabah, Malaysia
Hospital Ampang
Ampang, Selangor, Malaysia
Servicio de Hematologia del Hospital Universitario de la Uanl
Monterrey, Nuevo León, Mexico
Clinica San Felipe
Lima, Peru
St Lukes Medical Center
Quezon, Central Luzon, Philippines
Szpital Uniwersytecki Nr2 Bydgoszcz
Bydgoszcz, Poland
Institute of Hematology and Transfusion Medicine
Warsaw, Poland
University Clinical Center Medical University of Gdansk
Gdansk, Pomeranian Voivodeship, Poland
Ion Chiricuta Oncology Institute
Cluj-Napoca, Cluj, Romania
Municipal Hospital Filantropia
Craiova, Dolj, Romania
Targu Mures Clinical County Emergency Hospital
Târgu Mureş, Mureș County, Romania
National University Hospital
Singapore, Singapore
Pusan National University Hospital
Busan, South Korea
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.